BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks

By Patricia Miller


Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide investment decisions.

BAYER sign on top of building.
Bayer (OTC: BAYRY) Confronts Billion-Dollar Roundup Verdict and Drug Failure

What You Need To Know

Bayer AG (OTC: BAYRY) recently encountered significant challenges, impacting its market position and investor confidence. The German pharmaceutical and agricultural giant faced a substantial setback with its experimental anti-thrombotic drug, asundexian.

An independent panel revealed the drug underperformed compared to standard care in preventing stroke and systemic embolism in patients with atrial fibrillation. This led to halting a major study, notably just after Bayer sold bonds worth $5.75 billion, raising questions among investors and analysts about Bayer's awareness of the trial results beforehand.

Additionally, Bayer grapples with legal challenges concerning its Roundup weed killer. A recent Missouri jury verdict ordered Bayer's Monsanto unit to pay over $1.5 billion to three former Roundup users who attributed their cancers to the product.

This verdict is among the largest against a U.S. corporate defendant this year. Despite Bayer's stance on Roundup's safety and previous settlements, the company now faces a new wave of lawsuits, complicating potential corporate restructuring plans.

Bayer's shares and bonds suffered, marking the lowest levels in over a decade. The company's market value dropped by approximately €7.6 billion ($8.3 billion).

These developments increase pressure on CEO Bill Anderson, who joined Bayer amid challenges from the Monsanto acquisition and impending patent expirations of key treatments.

Anderson's leadership now focuses on potentially restructuring the conglomerate, balancing the need for strategic decisions in both the pharmaceutical and agricultural sectors.

Why This Is Important for Retail Investors

  1. Impact on Stock Value: Retail investors need to pay close attention as Bayer's challenges, including the halted drug trial and the Roundup verdict, have led to a significant drop in BAYRY stock value. This decline impacts the value of investments held in Bayer's stocks, making it crucial for investors to reassess their portfolios and consider the long-term viability of holding these shares.

  2. Risk Assessment: The recent developments highlight the importance of comprehensive risk assessment for retail investors. The combination of legal issues and failed drug trials at Bayer underscores the potential for sudden and significant risks that can arise in the pharmaceutical and agricultural sectors. Understanding these risks is key for investors in making informed decisions about where to allocate their resources.

  3. Corporate Governance and Management Decisions: The way Bayer's management handles these crises is critical. CEO Bill Anderson's decisions on potential restructuring and navigating the company through these challenges will significantly influence the company's future prospects. Retail investors should monitor management's actions and strategies, as they can have a direct impact on the company's recovery and future growth.

  4. Legal and Regulatory Environment: The Roundup verdicts and their implications on Bayer's financials demonstrate the impact of the legal and regulatory environment on corporate performance. Retail investors need to be aware of how such external factors can affect a company's operations and financial health, influencing their investment decisions.

  5. Market Sentiment and Confidence: Bayer's situation, and subsequent BAYRY stock drop, is a reminder of how market sentiment and investor confidence can be volatile, especially in industries like pharmaceuticals and agriculture where product efficacy and safety are paramount. Investors should consider market sentiment and its potential impact on stock prices and investment stability, adapting their strategies to manage these fluctuations effectively.

Sign up for Investing Intel Newsletter

How Can You Use This Information?

Here are some of the investing ideas that can be explored using this information:

Value Investing

Investors may see an opportunity in Bayer's lowered stock price, considering it a value buy. If the belief is that the company's fundamentals remain strong and it can recover from its current setbacks, purchasing BAYRY stock at a reduced price could yield long-term benefits. However, this approach requires a thorough analysis of Bayer's financial health, market position, and potential for recovery.

Value investing searches for undervalued companies that trade for less than their intrinsic values, with the expectation that they will eventually be recognized by the market.

Growth Investing

For those focusing on growth, Bayer's situation might lead them to look for alternative companies in the pharmaceutical and agricultural sectors that are positioned for higher growth. These alternatives might be companies with more stable legal standings and promising pipelines of innovative products. This strategy involves identifying companies that are expected to grow at an above-average rate compared to their industry or the overall market.

Growth investing focuses on stocks of companies expected to grow at an above-average rate compared to other stocks in the market; learn more in our article titled 'What is Growth Investing?'.

Momentum Investing

Investors might use Bayer's situation to engage in momentum investing, either by betting against the company (if they believe the stock will continue to decline) or by watching for a turnaround in Bayer's stock as a signal to buy. This approach involves capitalizing on existing market trends and requires a keen understanding of market sentiment and technical analysis.

Momentum investing rides the wave of existing market trends by buying assets that have shown an upward price trend and selling those in a downtrend.

Defensive investing

Considering the volatility in Bayer's market segment, investors might lean towards more defensive investments. These could be in sectors less susceptible to the kind of legal and product efficacy issues impacting Bayer, such as utilities or consumer staples, which tend to offer more stability during market fluctuations.

Defensive Investing focuses on securing a portfolio by choosing companies that are less sensitive to economic downturns.


Bayer's challenges underscore the importance of diversification. Investors could use this as an impetus to diversify their portfolios, spreading investments across various sectors and companies to mitigate risks associated with any single company or industry.

Diversification spreads investments across various assets to reduce risk and volatility in a portfolio.

Read What Others Are Saying

Bloomberg: Bayer Slumps Most Ever After Roundup Verdict, Drug Setback

Reuters: Exclusive: Bayer holds call with bond investors after raft of bad news

The Wall Street Journal: Bayer Stock Plunges After Negative Drug-Trial Result

FT: Bayer drug setback adds to new CEO's problems

What you should read next:

Relevant ETFs

Some investors prefer to invest in stocks via an exchange-traded fund for ease and reduced risk. Some popular ETFs include the following:

  • Large-Caps: Vanguard Mega Cap ETF (MGC)

  • Mid-Caps: Vanguard Mid-Cap ETF (VO)

  • Small-Caps: Vanguard Small-Cap ETF (VB)

  • Growth: iShares Core S&P U.S. Growth ETF (IUSG)

  • Value: iShares Core S&P US Value ETF (IUSV)

  • Developed Markets: Vanguard FTSE Developed Markets ETF (VEA)

  • Commodities: iShares S&P GSCI Commodity Indexed Trust (GSG)

  • Obesity and Heart Disease: Tema Cardiovascular and Metabolic ETF (HRTS)

Investing with Insight

Knowing where to invest is not easy. Bullish and bearish sentiment is always vying for control, and investors like you can very quickly become overwhelmed.

And yet, no matter what the wider stock market is doing, there are always little-known gems to uncover. 

One potential growth stock flying under the radar is a dynamic company operating at the forefront of the entertainment industry. This business is diverse and multifaceted and led by industry veterans with extensive experience in entertainment and investment.

This high-potential US stock is targeting India’s tech-hungry 1.4 billion people.

Internet and social media adoption in India is surging, and the country has the LARGEST youth population worldwide. Over 650M people are under 25 years old, and 850M are under 35 years old. 

With rising economic and educational prospects, the country is a hotbed for digital engagement.

Some highlights you’ll want to know include:

  • This is one of the fastest-growing creator-media companies in India and the United States.

  • This company reaches 1 billion global consumers every month.

  • India was the second-fastest-growing market in the influencer marketing space in 2022. 

  • Global influencer marketing spend is expected to reach $34 billion in 2023.

  • This company has posted nine consecutive quarters of YoY growth, representing a 33% CAGR using its repeatable content strategy.

  • This impressive small-cap has just appointed a former TikTok Country manager as its India Group CEO. 

Finally, this stock is analyst-backed with a potential 114% upside from the analyst initiation date.

If you're intrigued by this stock’s promising prospects, why not take a closer look?


In this article:


Author: Patricia Miller

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter